Efficacy
In the CORAL study, the 3-year EFS rate was 31% (95% CI, 26% to 36%) and was not significantly different between the R-ICE and R-DHAP arms (26% and 35%, respectively; P=0.6). Three-year PFS was 37% (95% CI, 31% to 42%), and the R-ICE and R-DHAP arms were not significantly different (31% and 42%, respectively; P=0 .4). Three-year OS was 49% (95% CI, 43% to 55%), with no difference between the R-ICE and R-DHAP arms (47% and 51%, respectively; P=0.4). For patients who underwent ASCT, 3-year PFS was 53%. There was no difference between the numbers of patients who achieved CR (38%) and PR prior to ASCT. Response rates, PFS and OS were all significantly affected by prior use of rituximab, early relapse (<12 months) and the secondary IPI (prognostic index) (see Table 3 below).r In the earlier, non-randomised study the CR rate with R-ICE was 53% compared with 27% in historical controls treated with ICE (see Table 4 below). The PFS in this group was 54% at 2 years.r
© Journal of Clinical Oncology 2010
© Blood 2004